Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

As previously reported in a Current Report on Form 8-K filed on June 20, 2024, Aimei Health Technology Co., Ltd (the "Company" or "Aimei Health") entered into a definitive business combination agreement dated June 19, 2024 (as amended, the "Business Combination Agreement"), with Aimei Investment Ltd, a Cayman Islands exempted company, in its capacity as the representative of the Company and the shareholders of the Company, United Hydrogen Global Inc., an exempted company with limited liability incorporated in the Cayman Islands ("Pubco"), United Hydrogen Victor Limited, an exempted company with limited liability incorporated in the Cayman Islands and a wholly owned subsidiary of Pubco (the "First Merger Sub"), United Hydrogen Worldwide Limited, an exempted company with limited liability incorporated in the Cayman Islands and a wholly owned subsidiary of Pubco (the "Second Merger Sub"), and United Hydrogen Group Inc., an exempted company with limited liability incorporated in the Cayman Islands ("United Hydrogen"). Pursuant to the Business Combination Agreement, subject to the terms and conditions set forth therein, at the closing of the transactions contemplated by the Business Combination Agreement, (i) the First Merger Sub will merge with and into United Hydrogen, with United Hydrogen surviving the First Merger as a wholly owned subsidiary of Pubco and the outstanding shares of United Hydrogen being converted into the right to receive shares of Pubco, and Pubco, First Merger Sub, and United Hydrogen shall cause the First Merger to be consummated by executing the First Merger Plan of Merger; and (ii) the Second Merger Sub will merge with and into Aimei Health, with Aimei Health surviving the Second Merger as a wholly owned subsidiary of Pubco and the outstanding securities of Aimei Health being converted into the right to receive shares of Pubco, and Pubco, Second Merger Sub, and Aimei Health shall cause the Second Merger to be consummated by executing the Second Plan of Merger (the transactions contemplated by the Business Combination Agreement and other ancillary documents, the "Business Combination").

On November 6, 2025, the Company held an extraordinary general meeting of shareholders of the Company (the "Extraordinary General Meeting") in the offices of the Company's counsel, Hunter Taubman Fischer & Li LLC, at 950 Third Avenue, 19th Floor, New York, NY 10022 and virtually online at www.virtualshareholdermeeting.com/AFJKU2025SM, pursuant to due notice. The board of directors of the Company fixed the close of business on September 26, 2025 as the Record Date for the determination of shareholders entitled to notice of and to vote at the Extraordinary General Meeting or at any adjournment thereof. On the Record Date, the Company had 6,121,733 ordinary shares issued and outstanding and holders of such shares were entitled to notice of and to vote at the Extraordinary General Meeting. At the Extraordinary General Meeting, holders of the Company's outstanding ordinary shares in attendance (represented in person or by proxy) voted on four proposals presented, the Business Combination Proposal, the Merger Proposal, the Share Issuance Proposal, and the Adjournment Proposal, each as described in the proxy statement dated October 10, 2025 (the "EGM Proxy Statement"). The shareholders represented in person or by proxy and entitled to vote at the Extraordinary General Meeting cast their votes as described below.

Capitalized terms used but not defined herein have the meaning given to them in the EGM Proxy Statement.